

25 Oct 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: a slow start for Biogen's Aduhelm; J&J looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from bluebird bio; UCB faces bimekizumab delays; and progress and setbacks in gene therapy.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 22 October 2021, including: a slow start for *Biogen, Inc.*'s Aduhelm; *Johnson & Johnson* looks to transition COVID vaccine to commercial sales; 2seventy bio spins out from *bluebird bio*; *UCB S.A.* faces bimekizumab delays; and progress and setbacks in gene therapy.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Biogen's Q3 Aduhelm Sales Even Worse Than Expected](#)" - Scrip, 20 Oct, 2021.)

(Also see "[J&J Expects A Commercial COVID-19 Vaccine Market By Late 2022/2023](#)" - Scrip, 19 Oct, 2021.)

(Also see "[Bluebird Spinoff 2seventy Bio Gets Its Own Wings](#)" - Scrip, 19 Oct, 2021.)

(Also see "[UCB Frustrated By FDA Failure To Inspect Facility For Psoriasis Drug](#)" - Scrip, 18 Oct, 2021.)

(Also see "[The Next Big Thing In Gene Therapy Might Not Be Gene Therapy](#)" - Scrip, 15 Oct, 2021.)

[Click here to explore this interactive content online](#) ✨